Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-)
Viruses · 2025
DOI: 10.3390/v17111462 ↗Kurz gefasst
Fallbericht in der Zeitschrift Viruses, 2025. Verfasst von Elena Seminari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Cytomegalovirus, Cytomegalovirus Infections, Drug Resistance, Viral. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The emergence of drug-resistant cytomegalovirus (CMV) complicates viral response to therapy. We present two cases of solid organ transplant (SOT) recipients, highlighting the reversion of UL97 mutations associated with val(ganciclovir) resistance. Patient 1, a heart transplant recipient, initially received pre-emptive treatment with val(ganciclovir), followed by foscarnet for recurrent CMV episodes. Mutations A594V in the UL97-kinase gene and V715M in the UL54-polymerase gene were detected. He developed CMV colitis and was then treated with maribavir. After discontinuing val(ganciclovir), genotyping revealed no resistance mutations. Following CMV DNA suppression, secondary prophylaxis with letermovir and val(ganciclovir) was initiated. Patient 2, a double-lung transplant recipient, experienced several CMV episodes. Initially treated with val(ganciclovir), he developed the L595S mutation in the UL97 kinase gene, conferring resistance. Therapy was then switched to foscarnet, which was suspended due to renal failure, and then to maribavir. Subsequently, the H411Y mutation in the UL97 was detected, conferring maribavir resistance, while val(ganciclovir) mutation was no longer detectable. He was then treated with val(ganciclovir) and letermovir, achieving undetectable CMV DNA, and then continued letermovir alone as prophylaxis. Detecting gene mutations that confer drug resistance is crucial for managing antiviral therapy when virological response is lacking. In our cases, the reversion of (va)ganciclovir-resistance mutations occurred after drug withdrawal, a previously unreported finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- Infectious Diseases Unit, ASST Papa Giovanni XXIII, 24100 Bergamo, Italy.
- Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy.
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy.
ORCID-Profile: Elena Seminari, Aurelia Sangani, Daniele Lilleri
Zitieren
APA
Seminari, E., Tebaldi, A., Sangani, A., Giordani, P., Lilleri, D., Paolucci, S., Campanini, G., Iskandar, E., Baldanti, F., & Bruno, R. (2025). Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-). Viruses. https://doi.org/10.3390/v17111462
Vancouver
Seminari E, Tebaldi A, Sangani A, Giordani P, Lilleri D, Paolucci S, et al. Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-). Viruses. 2025. doi:10.3390/v17111462
BibTeX
@article{Seminari2025,
author = {Seminari, Elena and Tebaldi, Alessandra and Sangani, Aurelia and Giordani, Paola and Lilleri, Daniele and Paolucci, Stefania and Campanini, Giulia and Iskandar, Elizabeth and Baldanti, Fausto and Bruno, Raffaele},
title = {Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-)},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17111462}
}
EUVIMED